• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Diabetes Res Clin Pract . Hyperglycemia is a strong predictor of poor prognosis in COVID-19

tetano

Editor, Senior Moderator
Diabetes Res Clin Pract


. 2020 Jul 23;108338.
doi: 10.1016/j.diabres.2020.108338. Online ahead of print.
Hyperglycemia is a strong predictor of poor prognosis in COVID-19


Sheng-Ping Liu[SUP] 1 [/SUP], Qin Zhang[SUP] 1 [/SUP], Wei Wang[SUP] 2 [/SUP], Min Zhang[SUP] 3 [/SUP], Chun Liu[SUP] 1 [/SUP], Xuefei Xiao[SUP] 1 [/SUP], Zongdao Liu[SUP] 4 [/SUP], Wen-Mu Hu[SUP] 1 [/SUP], Ping Jin[SUP] 5 [/SUP]



Affiliations

Abstract

Aims: The objective of this study is to explore the association between documented diabetes, fasting plasma glucose (FPG), and the clinical outcomes of Coronavirus disease 2019 (COVID-19) .
Methods: This retrospective study included 255 patients with COVID-19. Of these, 214 were admitted to isolation wards and 41were admitted to intensive care units (ICUs).Demographic, clinical, treatment, and laboratory data were collected and compared between ICU and non-ICU patients. Multivariable logistic regression models were used to explore the risk factors associated with poor clinical outcomes (ICU admission or death).
Results: There were significant changes in several clinical parameters in ICU patients (leukopenia, lymphopenia, elevated D-dimer, as well as higher levels of FPG, cardiac troponin, serum ferritin,IL-6, and high-sensitivity C-reactive protein)compared with non-ICU patients. The prevalence of known diabetes was substantially higher in ICU than non-ICU patients (31.7% vs. 17.8%, P=0.0408).Multivariable regression analysis showed that a history of diabetes [odds ratio (OR), 0.099; 95% confidence interval (CI), 0.016-0.627; P=0.014], high FPG at admission (OR, 1.587; 95% CI, 1.299-1.939, P<0.001), high IL-6 (OR, 1.01; 95% CI, 1.002-1.018, P=0.013), and D-dimer higher than 1 mg/L at admission (OR, 4.341; 95% CI, 1.139-16.547, P=0.032) were independent predictors of poor outcomes. Cox proportional hazards analysis showed that compared with FPG <7mmol/L, FPG levels of 7.0-11.1 mmol/L and ≥11.1mmol/L were associated with an increased hazard ratio (HR) for poor outcome (HR, 5.538 [95% CI, 2.269-13.51] and HR, 11.55 [95% CI, 4.45-29.99], respectively).
Conclusion: Hyperglycemia and a history of diabetes on admission predicted poor clinical outcomes in COVID-19.

Keywords: COVID-19; Diabetes; Hyperglycemia; SARS-CoV-2.
 
Back
Top Bottom